Document detail
ID

oai:HAL:hal-02521203v1

Topic
vaccination coverage Sjögren’s syndrome [SDV.IMM.VAC]Life Sciences [q-bio]... [SDV.MP]Life Sciences [q-bio]/Micr...
Author
Jacques, Morel Letaief, Hind Philippe, Guilpain Xavier, Mariette Bernard, Combe Lukas, Cedric
Langue
en
Editor

HAL CCSD;MDPI

Category

sciences: life sciences

Year

2020

listing date

12/8/2023

Keywords
3% low vaccine 0 coverage patients 95% pss ci influenza
Metrics

Abstract

International audience; Objective: To evaluate vaccination coverage and reasons for non-vaccination in patients with primary Sjögren's syndrome (pSS).

Method: A total of 111 patients fulfilling American-European Consensus Group criteria for pSS were interviewed by use of a standardized questionnaire between January 2016 and November 2017 in two French tertiary referral centers for auto-immune diseases.

Results: Updated immunization coverage for influenza was 31.5% (n = 35), pneumococcus was 11.7% (n = 13), and diphtheria-tetanus-poliomyelitis (DTP) was 24.3% (n = 27).

The main reasons for non-vaccination were fear of side effects from the influenza vaccine (40.3%) and a lack of proposal for the pneumococcal vaccine (72.3%).

In vaccinated patients, vaccination was mainly proposed by general practitioners for the influenza vaccine (42.6%) and rheumatologists for the pneumococcal vaccine (41.2%).

Probability of influenza vaccination was associated with age (odds ratio/year (OR) 1.04, 95% confidence interval (CI) 1.0-1.1; p = 0.016), history of severe infection (OR 15.9, 95% CI 1.35-186; p = 0.028), low EULAR Sjögren's syndrome disease activity index (OR 0.85, 95% CI 0.75-0.96; p = 0.013), and comorbidities (OR 3.52, 95% CI 1.22-10.2; p = 0.02).

Probability of vaccination against pneumococcus was associated with lung comorbidities (OR 3.83, 95% CI 1.11-13.12; p = 0.033) and up-to-date influenza vaccination (OR 3.71, 95% CI 1.08-12.8; p = 0.038).

Conclusion: Influenza, pneumococcal, and DTP vaccine coverage was low in patients with pSS included in this study.

These results underline the relevance of systematically screening vaccine status in pSS patients and educating patients and physicians on the need for vaccination to improve vaccine coverage in this population.

Jacques, Morel,Letaief, Hind,Philippe, Guilpain,Xavier, Mariette,Bernard, Combe,Lukas, Cedric, 2020, Low Influenza, Pneumococcal and Diphtheria–Tetanus–Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren’s Syndrome: A Cross-Sectional Study, HAL CCSD;MDPI

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw